首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC β-Lactamase: Implications for Antibiotic Use
【2h】

Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC β-Lactamase: Implications for Antibiotic Use

机译:产肠杆菌科细菌引起的AmpCβ-内酰胺酶感染的治疗过程中抗生素耐药性的出现:抗生素使用的意义。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii are characterized by chromosomally encoded AmpC β-lactamases and possess the ability to develop resistance upon exposure to broad-spectrum cephalosporins. To determine the incidences of the emergence of resistance during antimicrobial therapy for infections caused by these organisms and the effect of the emergence of resistance on patient outcomes, all patients who were admitted to the Asan Medical Center (Seoul, Republic of Korea) from January 2005 to June 2006 and whose clinical specimens yielded Enterobacter spp., S. marcescens, C. freundii, or M. morganii were monitored prospectively. The main end point was the emergence of resistance during antimicrobial therapy. A total of 732 patients with infections were included for analysis. The overall incidence of the emergence of antimicrobial resistance during antimicrobial therapy was 1.9% (14/732). Resistance to broad-spectrum cephalosporins, cefepime, extended-spectrum penicillin, carbapenem, fluoroquinolones, and aminoglycosides emerged during treatment in 5.0% (11/218), 0% (0/20), 2.0% (2/100), 0% (0/226), 0% (0/153), and 1.1% (1/89) of patients, respectively. The emergence of resistance to broad-spectrum cephalosporins occurred more often in Enterobacter spp. (8.3%, 10/121) than in C. freundii (2.6%, 1/39), S. marcescens (0%, 0/37), or M. morganii (0%, 0/21). Biliary tract infection associated with malignant bile duct invasion was significantly associated with the emergence of resistance to broad-spectrum cephalosporins (P = 0.024 at a significance level of 0.042, by use of the Bonferroni correction). Only 1 of the 14 patients whose isolates developed resistance during antimicrobial therapy died. The emergence of resistance was more frequently associated with broad-spectrum cephalosporins than with the other antimicrobial agents tested, especially in Enterobacter spp. However, the emergence of resistance was associated with a low risk of mortality.
机译:肠杆菌属,粘质沙雷氏菌,弗氏柠檬酸杆菌和摩根氏摩根氏菌的特征在于染色体编码的AmpCβ-内酰胺酶,并具有在暴露于广谱头孢菌素时产生抗性的能力。为了确定这些微生物引起的感染的抗微生物治疗期间出现耐药性的发生率以及耐药性出现对患者预后的影响,所有患者均自2005年1月起入住Asan医疗中心(大韩民国首尔)到2006年6月,对前者的临床标本进行了监测,其临床标本产生了肠杆菌属,marcescens,C。freundii或M. morganii。主要终点是在抗微生物治疗期间出现耐药性。总共732例感染患者被纳入分析。抗生素治疗期间出现抗生素耐药性的总发生率为1.9%(14/732)。治疗期间出现了对广谱头孢菌素,头孢吡肟,广谱青霉素,碳青霉烯,氟喹诺酮和氨基糖苷的耐药性,分别为5.0%(11/218),0%(0/20),2.0%(2/100),0% (0/226),0%(0/153)和1.1%(1/89)的患者。广谱头孢菌素耐药性的出现更常见于肠杆菌属。 (8.3%,10/121),比弗氏梭菌(2.6%,1/39),粘液链球菌(0%,0/37)或摩根摩根氏菌(0%,0/21)高。与恶性胆管浸润相关的胆道感染与对广谱头孢菌素的耐药性的出现显着相关(通过Bonferroni校正,P = 0.024,显着性水平为0.042)。在抗微生物治疗期间其分离株产生抗药性的14例患者中,只有1例死亡。与广谱头孢菌素相比,与其他测试的抗菌剂相比,耐药性的出现更常见,尤其是在肠杆菌属细菌中。但是,耐药性的出现与低死亡风险有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号